Device Trial Radar · NCT04808323
MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer
Last checked: Nov 20, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
22
Planned (sponsor's estimate)
Start
Jun 17, 2021
Primary completion
Apr 14, 2027
Study completion Jan 20, 2029
Sponsor
- Lead sponsor
- Medical College of WisconsinAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, open-label, phase I design.
Conditions
- Rectal Adenocarcinoma
Interventions
CapecitabineDrug
825 mg/m\^2 twice daily during radiation therapy. (Fluorouracil (5-FU) may be used at the discretion of the treating medical oncologists.) This chemotherapy will be given during the initial radiation dose (50 Gy over 25 frac) and continue for Cohorts A, B, and C.
Initial Dose of Radiation before Dose EscalationDevice
50 Gy over 25 frac.
Cohort A: Dose Escalation RadiationDevice
Cohort A will receive 14 Gy boost for a total of 64 Gy over 32 total fractions.
Cohort B: Dose Escalation RadiationDevice
Cohort B will receive 18 Gy boost for a total of 68 Gy over 34 total fractions.
Cohort C: Dose Escalation RadiationDevice
Cohort C will receive 22 Gy boost for a total of 72 Gy over 36 total fractions.
FOLFOXDrug
After the completion of radiation, subjects will receive up to eight cycles of systemic chemotherapy. (FOLFIRINOX may be used at the discretion of the treating medical oncologists.)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of subjects in Cohort A with serious adverse events during radiation.Time frame: Up to 11.5-week period
- The number of subjects in Cohort B with serious adverse events during radiation.Time frame: Up to 11.5-week period
- The number of subjects in Cohort C with serious adverse events during radiation.Time frame: Up to a 12.1-week period.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.